Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.verified

HALO

Price:

$38.71

Market Cap:

$4.92B

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to...[Read more]

Industry

Biotechnology

IPO Date

2004-03-16

Stock Exchange

NASDAQ

Ticker

HALO

The PE Ratio as of April 2024 (TTM) for Halozyme Therapeutics, Inc. (HALO) is 18.43

According to Halozyme Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 18.43. This represents a change of -5.24% compared to the average of 19.45 of the last 4 quarters.

Halozyme Therapeutics, Inc. (HALO) Historical PE Ratio (quarterly & annually)

How has HALO PE Ratio performed in the past?

The mean historical PE Ratio of Halozyme Therapeutics, Inc. over the last ten years is -0.03. The current 18.43 PE Ratio has changed -5274550.28% with respect to the historical average. Over the past ten years (40 quarters), HALO's PE Ratio was at its highest in in the March 2019 quarter at 325.99. The PE Ratio was at its lowest in in the December 2018 quarter at -238.51.

Quarterly (TTM)
Annual

Average

-0.03

Median

0.92

Minimum

-68.13

Maximum

45.07

Halozyme Therapeutics, Inc. (HALO) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Halozyme Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 293.44%

Maximum Annual PE Ratio = 45.07

Minimum Annual Increase = -459.83%

Minimum Annual PE Ratio = -68.13

Quarterly (TTM)
Annual
YearPE RatioChange
202317.32-55.05%
202238.52174.31%
202114.04-68.84%
202045.07-227.22%
2019-35.4235.59%
2018-26.12-159.52%
201743.89-459.83%
2016-12.20-82.10%
2015-68.13293.44%
2014-17.32-14.52%

Halozyme Therapeutics, Inc. (HALO) Average PE Ratio

How has HALO PE Ratio performed in the past?

The current PE Ratio of Halozyme Therapeutics, Inc. (HALO) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

23.29

5-year avg

15.90

10-year avg

-0.03

Halozyme Therapeutics, Inc. (HALO) PE Ratio vs. Peers

How is HALO’s PE Ratio compared to its peers?

Halozyme Therapeutics, Inc.’s PE Ratio is greater than Agios Pharmaceuticals, Inc. (-4.93), greater than Insmed Incorporated (-4.66), greater than Cerevel Therapeutics Holdings, Inc. (-16.98), greater than Ultragenyx Pharmaceutical Inc. (-5.84), less than BioMarin Pharmaceutical Inc. (100.61), greater than Seagen Inc. (-57.36), greater than Alnylam Pharmaceuticals, Inc. (-41.60), less than Exelixis, Inc. (33.96), greater than Alector, Inc. (-3.35), greater than Legend Biotech Corporation (-16.52), greater than Ascendis Pharma A/S (-15.66), greater than Cytokinetics, Incorporated (-12.52), greater than Edgewise Therapeutics, Inc. (-10.06), greater than Apellis Pharmaceuticals, Inc. (-10.93), greater than Blueprint Medicines Corporation (-10.88), greater than BeiGene, Ltd. (-15.46), greater than Inhibrx, Inc. (-7.64), greater than Protagonist Therapeutics, Inc. (-20.96), greater than DICE Therapeutics, Inc. (-23.17), greater than Larimar Therapeutics, Inc. (-7.84), greater than Viridian Therapeutics, Inc. (-2.99),

Build a custom stock screener for Halozyme Therapeutics, Inc. (HALO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Halozyme Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Halozyme Therapeutics, Inc. (HALO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Halozyme Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Halozyme Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Halozyme Therapeutics, Inc. (HALO)?

What is the highest PE Ratio for Halozyme Therapeutics, Inc. (HALO)?

What is the 3-year average PE Ratio for Halozyme Therapeutics, Inc. (HALO)?

What is the 5-year average PE Ratio for Halozyme Therapeutics, Inc. (HALO)?

How does the current PE Ratio for Halozyme Therapeutics, Inc. (HALO) compare to its historical average?